The use of orthopedic implants or tumor necrosis factor inhibitors doubled the risk for bone infections in patients with RA who had contracted S aureus bacteremia.
The U.S. health regulator approved Basilea Pharmaceutica's antibiotic for bacterial infections including multidrug-resistant strains, the FDA said on.